10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

FAM189B Antibody (Center)

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP21802c

Product Information

Application	WB, E
Primary Accession	P81408
Reactivity	Human, Mouse
Predicted	Rat, Bovine, Canine, Rabbit
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit IgG
Clone Names	RB54107
Calculated MW	71355

Additional Information

Gene ID	10712
Other Names	Protein FAM189B, Protein COTE1, FAM189B, C1orf2, COTE1
Target/Specificity	This FAM189B antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 365-400 amino acids from the Central region of human FAM189B.
Dilution	WB~~1:2000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	FAM189B Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.


Protein Information

Name	ENTREP3 (HGNC:1233)
Cellular Location	Membrane; Multi-pass membrane protein
Tissue Location	Widely expressed.

References

Winfield S.L.,et al.Genome Res. 7:1020-1026(1997).
Gregory S.G.,et al.Nature 441:315-321(2006).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Ludes-Meyers J.H.,et al.Oncogene 23:5049-5055(2004).
Dephoure N.,et al.Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).

Images



All lanes : Anti-FAM189B Antibody (Center) at 1:2000 dilution Lane 1: human heart lysate Lane 2: Jurkat whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 71 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.